TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19278087
Drug: Rotation-oscillation toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotation-oscillation toothbrush (Oral-B Triumph)
Study: 12028504
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg day-1)
Study: 12534449
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg day-1)
Study: 25076
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg kg‐1
Study: 28120591
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (0.2 mg/kg daily for 3 days)
Study: 20061726
Drug: Control lotion
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control lotion applied daily for 10 weeks
Study: 18070245
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/d
Study: 9865813
Drug: High structured
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High structured treatment
Study: 333906
Drug: Bovine lung
Normalized name: defibrotide, bovine lung
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lung heparin (2 units/ml)
Study: 333906
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of bovine lung heparin and porcine intestinal heparin
Study: 20687931
Drug: Polypill-based strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill-based strategy (single capsule containing aspirin, a statin, and two blood pressure-lowering agents)
Study: 18272344
Drug: Serrapeptase 5mg
Normalized name: Serrapeptase
DrugBank: Serrapeptase (DB13131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serrapeptase 5mg + 1000 mg paracetamol
Study: 18272344
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 1000 mg paracetamol
Study: 16167356
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg twice a day for 3 days)
Study: 408844
Drug: d-amphetamine 10
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 10 mg
Study: 8719123
Drug: pimozide 1
Normalized name: pimozide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimozide 1 mg
Study: 8719123
Drug: pimozide 2
Normalized name: pimozide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimozide 2 mg
Study: 1389818
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 0.125% bupivacaine (group B)
Study: 3885918
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E2 (PGE2)
Study: 28631234
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of the PATHS curriculum
Study: 24939489
Drug: Sevoflurane (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (1.0 MAC) + low-dose i.v. remifentanil (0.028 μg/kg per minute)
Study: 20594220
Drug: Mosapride 15
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 15 mg/day
Study: 9692655
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg/day
Study: 15943844
Drug: Tandospirone 30
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone 30 mg/day
Study: 27933348
Drug: Drug-based treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-based treatment (NSAIDs only)
Study: 18158850
Drug: Pure substances
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure substances in hard gelatin capsules (reference)
Study: 15867044
Drug: CCK‐OP (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐OP (0.04 mug/kg per dose, twice daily)
Study: 7543598
Drug: Zanoterone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanoterone 200 mg
Study: 1298631
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine bisulfate 10mg/kg 8 hourly for a total of 7 days when patients were well enough (after initial loading dose)
Study: 1298631
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without initial loading dose
Study: 6470965
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (3000 mg of salicylate)
Study: 6470965
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage schedules
Study: 30772699
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) treatment
Study: 12183351
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion of lisuride
Study: 12183351
Drug: Oral levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral levodopa and dopamine agonists (control)
Study: 3689626
Drug: DPI 201-106
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI 201-106 (30 mg)
Study: 3689626
Drug: DPI 201-106
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI 201-106 (60 mg)
Study: 20388917
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline and ciprofloxacin 2 × 200 mg/d intravenously (placebo group)
Study: 18427974
Drug: Letrozole 5
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5 mg/day (n = 70) on days 3-7 of the menstrual cycles
Study: 18427974
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day combined with human menopausal gonadotropin (hMG) 75 IU/ml
Study: 12588933
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg reboxetine
Study: 12841697
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg vaginal misoprostol 6 hourly (group 1, n = 60)
Study: 1400933
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) buserelin continued during HMG treatment
Study: 3890510
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg every 12 hours during low-dose week, 300 mg every 8 hours during high-dose week)
Study: 27912951
Drug: Homeopathic cold
Normalized name: Boiron Homeopathic Cold Calm Cold Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic cold syrup
Study: 16019355
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 40 mg plus estradiol valerate 2 mg daily
Study: 12626215
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus estradiol valerate 2 mg daily
Study: 9925834
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25 mg once daily (QD)
Study: 9925834
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25 mg twice a day (BID)
Study: 9925834
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg BID
Study: 9925834
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg QD
Study: 656715
Drug: In-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient treatment for three months
Study: 28257617
Drug: 2 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sessions of cervicothoracic manipulation and range‐of‐motion exercises followed by 6 sessions of stretching and strengthening exercise (manipulative‐therapy‐plus‐exercise group)
Study: 25951477
Drug: Daily cleaning
Normalized name: Oxy Daily Cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cleaning with multipurpose disinfection solution (MPDS)
Study: 25951477
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no daily cleaning)
Study: 18327066
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers
Study: 6134467
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate
Study: 6134467
Drug: 2 percent
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GEL [The Keeps ETHANOL 62 percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 percent nitroglycerin ointment
Study: 24399088
Drug: Ampicillin or
Normalized name: ampicillin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin or Amoxicillin
Study: 21537858
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field at radiofrequencies, 30 min daily, 5 consecutive days per week for 2 weeks
Study: 11705489
Drug: Imatinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (various doses)
Study: 20056639
Drug: Interactive, tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive, tailored computer instruction at baseline and four monthly lay health advisor counseling sessions
Study: 20056639
Drug: Low-dose comparison
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose comparison group consisting of a culturally appropriate mammography screening pamphlet
Study: 8681493
Drug: Mazapertine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazapertine (20 or 30 mg)
Study: 8681493
Drug: Mazapertine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazapertine (40 mg)
Study: 8681493
Drug: Mazapertine (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazapertine (incremental dosing)
Study: 1920817
Drug: Ketanserin (KET)
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (KET) 40 mg
Study: 6227244
Drug: megadose multi-vitamin/mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: megadose multi-vitamin/mineral supplement for 4 months
Study: 14978984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug)
Study: 25491391
Drug: MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC treatment in combination with everolimus and prednisolone
Study: 25491391
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving everolimus, prednisolone, and standard dose tacrolimus
Study: 17985420
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy (Group 1)
Study: 17985420
Drug: Step‐up to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐up to combination therapy (Group 2)
Study: 11896097
Drug: Postoperative hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative hepatic arterial floxuridine combined with intravenous continuous‐infusion fluorouracil (chemotherapy arm)
Study: 9036320
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm)
Study: 15722809
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use
Study: 31095954
Drug: PPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV plus IVB (1.25 mg bevacizumab)
Study: 20154071
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (control)
Study: 22222299
Drug: Citracal Petite
Normalized name: Citracal Petites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citracal Petite (tablet formulation of calcium citrate)
Study: 20214047
Drug: Serum insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum insulin-like growth factor-1 (IGF-1) level
Study: 9863095
Drug: Ginkgo leave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo leave concentrated oral liquor (GLC)
Study: 25178668
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose)
Study: 24314422
Drug: Anterior chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior chamber paracentesis (ACP) and medical treatment (group 1)
Study: 3518423
Drug: Tunneled subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunneled subcutaneous catheters
Study: 24802090
Drug: Five 1‐hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 1‐hr milieu communication teaching (MCT) sessions per week (daily treatment)
Study: 24802090
Drug: Parental linguistic
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental linguistic mapping measured after 6 months of treatment
Study: 3174738
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4 mg)
Study: 1559737
Drug: Vehicle for
Normalized name: ORAL SUSPENDING COMPOUND PLUS SUSPENSION VEHICLE (VEHICLE FOR ORAL SUSPENSION)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle for ciclopirox olamine cream
Study: 23062392
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100 μg once daily
Study: 23062392
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 200 μg once daily
Study: 22342538
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 μg twice daily
Study: 18343264
Drug: Levetiracetam 5000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 5000 mg
Study: 8750042
Drug: 7% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% CO2 inhalation
Study: 17547588
Drug: Topiramate (25-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25-600 mg/day)
Study: 10555933
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice/day
Study: 10555933
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice/day
Study: 15741734
Drug: Quinapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (ACE inhibitor)
Study: 26963851
Drug: Capsaicin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.1 mg) injected into the intermetatarsal space
Study: 26963851
Drug: Capsaicin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.1 mg)
Study: 12843167
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (10 mg atorvastatin and 900 mg gemfibrozil)
Study: 8635380
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Morphine plus 25 mg Promethazine (M-P)
Study: 8635380
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Morphine plus 10 mg Prochlorperazine (M-PC)
Study: 1461870
Drug: Dopamine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (high doses)
Study: 1461870
Drug: Dobutamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (low doses)
Study: 1461870
Drug: Dopamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (low doses)
Study: 3867301
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation (24Gy) plus i.t. MTX, 6 doses (Modality A)
Study: 3867301
Drug: i.t. MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. MTX and ARA-C, 10 doses (6 weekly and 4 monthly) (Modality B)
Study: 3867301
Drug: Standard-risk (SR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-risk (SR) therapy with PRED, VCR, ASPAR for remission induction and MP and MTX for maintenance
Study: 3867301
Drug: High-risk (HR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk (HR) therapy with 4 drugs including DAUNO, PRED, VCR, and DAUNO for reinductions every 3 months
Study: 22859563
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) with a median dose of 60 Gy and median OTT of 47 days
Study: 22859563
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time (OTT) ≤42 days
Study: 19841476
Drug: Nelotanserin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelotanserin (up to 40 mg)
Study: 17914653
Drug: Ropivacaine 0.54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.54 percent continuous wound infusion
Study: 17914653
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline continuous wound infusion
Study: 12850358
Drug: Pnc PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pnc PS vaccine (N=106)
Study: 8904969
Drug: Alcohol intoxication
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intoxication in women (both normally cycling and those taking oral contraceptives)
Study: 7093092
Drug: Labetalol 100
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 100 mg orally twice daily
Study: 7093092
Drug: Labetalol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 0.6 mg/kg intravenous dose
Study: 24301248
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% spray (CPS)
Study: 18677673
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle modification and pharmacological treatment
Study: 15960709
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin - 800,000 U penicillin G potassium twice daily for 12 days, repeated every 3 months for 1 year
Study: 15960709
Drug: Diethylcarbamazine -
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine - 6 mg/kg bodyweight for 12 days, repeated every 3 months for 1 year
Study: 15960709
Drug: Topical antiseptic
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptic (betadine ointment)
Study: 12505919
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV weight‐adjusted infusion of remifentanil (RIVA)
Study: 12505919
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion for remifentanil (TCIR)
Study: 30853260
Drug: Fluoroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically guided injections into the joint capsule (group 1)
Study: 30853260
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections to the point of maximum tenderness using sham radiographs (group 2)
Study: 30853260
Drug: Fluoroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically guided injections (group 1)
Study: 30853260
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections (group 2)
Study: 17609220
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid (20 mg of prednisolone)
Study: 9059095
Drug: Laryngeal mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal mask (group L)
Study: 2425671
Drug: Combined Urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Urokinase (UK) and Dextran Sulfate (DS) - UK: 2.84 X 10(5) units and DS: 3000 mg for one day
Study: 16433601
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (acetaminophen 650 mg every 6 h for temperature >38.5 degrees C and cooling blanket for temperature >39.5 degrees C)
Study: 16433601
Drug: Permissive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive treatment (no treatment for temperature >38.5 degrees C, treatment initiated at temperature >40 degrees C with acetaminophen and cooling blankets)
Study: 18398080
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment
Study: 16433601
Drug: Permissive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive treatment
Study: 14597105
Drug: Interferon (IFN)-beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon (IFN)-beta-1a (Rebif(R)) therapy for 1 year